nsclc: rapid progression data in the revel trial
Published 6 years ago • 301 plays • Length 6:53Download video MP4
Download video MP3
Similar videos
-
4:14
clinical implications of the revel trial in nsclc
-
6:18
treating nsclc with ramucirumab: the revel trial
-
2:26
the phase 3 revel trial in nsclc
-
3:09
key points from the revel trial in nsclc
-
5:49
various forms of disease progression in advanced nsclc
-
1:05
dr. brahmer on the impower150 trial in nsclc
-
6:51
progression in alk nsclc after frontline therapy
-
4:22
dr awad on the fda approval of perioperative nivolumab for resectable nsclc
-
4:16
ramucirumab data for lung cancer
-
6:11
patient selection for ramucirumab in nsclc
-
0:56
dr. stinchcombe on the alta-1l trial in alk nsclc
-
1:00:44
practical application of recent clinical data for immunotherapy in nsclc
-
5:42
non-driver nsclc: clinical decisions in rapidly progressing disease
-
1:50
anti-vegf therapy in advanced squamous nsclc
-
2:11
dr. kim discusses data from the impower150 trial in nonsquamous nsclc
-
2:20
adjuvant osimertinib in resected egfrm nsclc: the os data from the adaura trial
-
2:37
exploratory analysis of frontline therapies in revel: phase 3 trial of ramucirumab in nsclc
-
10:34
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
5:15
metastatic nsclc: a look at the impower150 trial